



Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via [InvestorWire](#) - Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by [NetworkNewsWire](#) ("NNW"), one of 70+ brands within the [Dynamic Brand Portfolio@IBN \(InvestorBrandNetwork\)](#), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

To view the full publication, "Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability," please visit: <https://nnw.fm/37Awq>

The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral and intravenous treatments continue to face significant challenges, chief among them low bioavailability and inadequate tumor targeting. These factors often limit the success of these treatments in clinical settings. Breakthroughs in nanomedicine are now addressing these obstacles, with growing support from the U.S. Food and Drug Administration (FDA), along with other regulators for nanocarrier-based delivery technologies used in advanced therapeutics.

This accelerating adoption highlights a broader shift across the industry: a race to optimize how medicines are transported, absorbed, and activated within the human body. Oncotelic Therapeutics Inc. is at the forefront of this movement with its proprietary Deciparticle(TM) platform, designed to enhance both the bioavailability and therapeutic index of existing oncology drugs. By improving the performance of underutilized compounds, the technology could help redefine standards for cancer treatment.

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company's mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu's leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic's strategic position in oncology and rare disease therapeutics.

For further information, please visit the company's website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company's newsroom at <https://ibn.fm/OTLC>

About NetworkNewsWire

[NetworkNewsWire](#) ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the [Dynamic Brand Portfolio @ IBN](#) that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and [editorial syndication to 5,000+ outlets](#); (3) [press release enhancement](#) to ensure maximum impact; (4) [social media distribution](#) via IBN to millions of social media followers; and (5) a full array of tailored [corporate communications solutions](#). With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit <https://www.NetworkNewsWire.com>

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: <https://www.NetworkNewsWire.com/Disclaimer>

NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by [IBN](#)

ONCOTELIC
THERAPEUTICS

10/30/2025 8:30:00 AM